Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma

B‐cell lymphoma, Unclassifiable with features intermediate between diffuse large B‐cell lymphoma (DLBCL) and Burkitt lymphoma, for convenience referred to here as unclassifiable B‐cell lymphoma, is a category in the 2008 World Health Organization system used for a group of histologically aggressive neoplasms that are difficult to classify definitively. Currently, there is no established standard therapy for these neoplasms.

[1]  A. Bagg,et al.  B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma , 2012 .

[2]  L. Medeiros,et al.  Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. , 2011, American journal of clinical pathology.

[3]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[4]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Carbone,et al.  B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. , 2010, Human pathology.

[6]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[7]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[8]  E. Obermann,et al.  Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.

[9]  N. Nakamura,et al.  Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations , 2009, Haematologica.

[10]  I. Miura,et al.  Clinical significance of 8q24/c‐MYC translocation in diffuse large B‐cell lymphoma , 2009, Cancer science.

[11]  R. Siebert,et al.  Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge , 2008, Leukemia.

[12]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[13]  L. Medeiros,et al.  Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations , 2008, Modern Pathology.

[14]  P. Moreau,et al.  The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement , 2007, Haematologica.

[15]  R. Zini,et al.  High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis , 2007, Haematologica.

[16]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[17]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[18]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[19]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[20]  L. Medeiros,et al.  Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis , 2006, Modern Pathology.

[21]  G. Rassidakis,et al.  Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein: A clinicopathologic study of 26 cases , 2005 .

[22]  G. Rassidakis,et al.  Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. , 2005, American Journal of Clinical Pathology.

[23]  R. Gascoyne,et al.  Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.